A Acute Promyelocytic Leukemia and Nursing Management: Literature Review


Article Sidebar

PDF 246
Published: Oct 29, 2023
Keywords:
Acute Promyelocytic Leukemia, ATRA therapy, Nursing role in APL
Section
Articles
Statistic

Main Article Content

Parveen Parveen
a:1:{s:5:"en_US";s:29:"Dr.BRAIRCH, AIIMS , NEW DELHI";}
vijay kumar
AIIMS, JODHPUR
https://orcid.org/0000-0002-9445-2600

Abstract

Aim of the study: This study is aimed to review the disease trajectory of APL, to describe the advances in research and clinical practice and their impact on patient outcomes.  Methodology: A computerized literature search of the PubMed, Cochrane, Medline and google scholar databases in the English language was conducted using the key words “acute promyelocytic leukemia” with subheadings “anthracycline,” “all-trans retinoic acid,” “arsenic trioxide,” “retinoic acid/differentiation syndrome,” “Q-T prolongation,” “disseminated intravascular coagulation” (DIC), “stem cell transplantation,” and “febrile neutropenia” without specifying the year of publication.  Results: Remission induction deaths continue to represent one of the major stumbling blocks in modern therapy of APL. Many studies reported that hemorrhage is the single most common cause of death (~5%) during induction therapy, followed by infection (~2-3%) and differentiation syndrome (~1.4%) in patients with APL receiving ATRA and idarubicin (AIDA regimen). Maximum lethal hemorrhages occurred early during induction, while infection and Differentiation syndrome became cause of deaths at later stages of treatment regime. An increased WBC count has been reported as an independent prognostic factor of response to induction therapy in many studies. Conclusion: Maximum deaths are happening during induction therapy; over that these are happening even before the initiation of the treatment. So, it become very critical for Oncology nurses to get acquaint themselves with the nuances of APL to play a proactive role in its management.

Article Details


How to Cite
Parveen, P., & vijay kumar. (2023). A Acute Promyelocytic Leukemia and Nursing Management: Literature Review. The WOCSI Journal of Medical Science, 1(01 (October-December) 2023), 7–14. Retrieved from https://twjms.wocsi.org/index.php/1/article/view/24

References

  1. References:
  2. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998 Nov 5;339(19):1341–8.
  3. Degos L, Wang ZY. All trans retinoic acid in acute promyelocytic leukemia. Oncogene. 2001 Oct;20(49):7140.
  4. Vaske MK, Tomi-Olugbodi A, Varadarajan I, Hou JS. Acute Promyelocytic Leukemia: An Unsual Presentation. Blood. 2015 Dec 3;126(23):4977–4977.
  5. Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009 Feb 26;113(9):1875–91.
  6. Walker DK, Held-Warmkessel J. Acute promyelocytic leukemia: an overview with implications for oncology nurses. Clin J Oncol Nurs. 2010 Dec;14(6):747–59.
  7. Freeman SD, Jovanovic JV, Grimwade D. Development of Minimal Residual Disease–Directed Therapy in Acute Myeloid Leukemia. Semin Oncol. 2008 Aug 1;35(4):388–400.
  8. Asou N, Adachi K, Tamura U, Kanamaru A, Kageyama S, Hiraoka A, et al. Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG). Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S65-71.
  9. Testa U, Lo-Coco F. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients. Ann Hematol. 2016 Apr;95(5):673–80.
  10. Brown P, Small D. FLT3 Inhibitors: a paradigm for the development of targeted therapeutics for paediatric cancer. Eur J Cancer. 2004 Mar 1;40(5):707–21.
  11. Serna J de la, Montesinos P, Vellenga E, Rayón C, Parody R, León A, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 2008 Apr 1;111(7):3395–402.
  12. Soignet SL, Maslak P, Wang Z-G, Jhanwar S, Calleja E, Dardashti LJ, et al. Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide. N Engl J Med. 1998 Nov 5;339(19):1341–8.
  13. Mi J-Q, Li J-M, Shen Z-X, Chen S-J, Chen Z. How to manage acute promyelocytic leukemia. Leukemia. 2012 Aug;26(8):1743–51.
  14. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol: Presented in part at the 39th meeting of the American Society of Hematology, New Orleans, LA, December 1999. Blood. 2002 Dec 15;100(13):4298–302.
  15. Kelaidi C, Chevret S, De Botton S, Raffoux E, Guerci A, Thomas X, et al. Improved Outcome of Acute Promyelocytic Leukemia With High WBC Counts Over the Last 15 Years: The European APL Group Experience. J Clin Oncol. 2009 May 4;27(16):2668–76.
  16. Cashin R, Burry L, Peckham K, Reynolds S, Seki JT. Acute renal failure, gastrointestinal bleeding, and cardiac arrhythmia after administration of arsenic trioxide for acute promyelocytic leukemia. Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm. 2008 May 15;65(10):941–6.
  17. Rego EM, Pandolfi PP. Analysis of the molecular genetics of acute promyelocytic leukemia in mouse models. Semin Hematol. 2001 Jan;38(1):54–70.
  18. Fenaux P, Chomienne C, Degos L. All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Semin Hematol. 2001 Jan;38(1):13–25.
  19. Ng C-H, Chng W-J. Recent advances in acute promyelocytic leukaemia. F1000Research [Internet]. 2017 Jul 28 [cited 2019 Aug 4];6. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538034/
  20. Mi J-Q, Li J-M, Shen Z-X, Chen S-J, Chen Z. How to manage acute promyelocytic leukemia. Leukemia. 2012 Aug;26(8):1743–51.
  21. Lo-Coco F, Ammatuna E, Montesinos P, Sanz MA. Acute promyelocytic leukemia: recent advances in diagnosis and management. Semin Oncol. 2008 Aug;35(4):401–9.
  22. ATRA-for-Acute-Myeloid-Leukaemia-AML-Web-Version.pdf [Internet]. [cited 2019 Aug 7]. Available from: https://media.leukaemiacare.org.uk/wp-content/uploads/ATRA-for-Acute-Myeloid-Leukaemia-AML-Web-Version.pdf
  23. Wang R, Zhang J, Wang S, Wang M, Ye T, Du Y, et al. The Cardiotoxicity Induced by Arsenic Trioxide is Alleviated by Salvianolic Acid A via Maintaining Calcium Homeostasis and Inhibiting Endoplasmic Reticulum Stress. Molecules. 2019 Jan;24(3):543.
  24. Jing Y. The PML-RARα Fusion Protein and Targeted Therapy for Acute Promyelocytic Leukemia. Leuk Lymphoma. 2004 Apr 1;45(4):639–48.
  25. Bryant AL, Walton A, Albrecht TA. Management of Febrile Neutropenia in a Patient With Acute Leukemia. J Emerg Nurs JEN Off Publ Emerg Dep Nurses Assoc. 2014 Jul;40(4):377–81.
  26. Lakshmaiah KC, Malabagi AS, Govindbabu, Shetty R, Sinha M, Jayashree RS. Febrile Neutropenia in Hematological Malignancies: Clinical and Microbiological Profile and Outcome in High Risk Patients. J Lab Physicians. 2015;7(2):116–20.
  27. Belay Y, Yirdaw K, Enawgaw B. Tumor Lysis Syndrome in Patients with Hematological Malignancies. J Oncol [Internet]. 2017 [cited 2019 Aug 9];2017. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688348/
  28. Alakel N, Middeke JM, Schetelig J, Bornhäuser M. Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase. OncoTargets Ther. 2017 Feb 2;10:597–605.
  29. Chen K-H, Liu H-C, Liang D-C, Hou J-Y, Huang T-H, Chang C-Y, et al. Minimally early morbidity in children with acute myeloid leukemia and hyperleukocytosis treated with prompt chemotherapy without leukapheresis. J Formos Med Assoc. 2014 Nov 1;113(11):833–8.
  30. Rust DM, Soignet SL. Risk/Benefit Profile of Arsenic Trioxide. The Oncologist. 2001 Apr 1;6(Supplement 2):29–32.
  31. 567.full.pdf [Internet]. [cited 2019 Jul 12]. Available from: http://www.bloodjournal.org/content/bloodjournal/72/2/567.full.pdf